Denali Therapeutics Inc.
DNLI
$19.80
$0.341.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 0.18% | 5.63% | 2.01% | 3.24% | 23.81% |
| Gross Profit | -0.18% | -5.63% | -2.01% | -3.57% | -1,157.64% |
| SG&A Expenses | 28.45% | 29.52% | 26.98% | 16.02% | 7.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.19% | 10.65% | 6.89% | 5.79% | 0.74% |
| Operating Income | -6.19% | -10.65% | -6.89% | -6.06% | -138.48% |
| Income Before Tax | -11.91% | -21.23% | -16.66% | -14.14% | -230.78% |
| Income Tax Expenses | 50.00% | 50.00% | 126.67% | 126.67% | 126.67% |
| Earnings from Continuing Operations | -11.91% | -21.23% | -16.67% | -14.15% | -230.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.91% | -21.23% | -16.67% | -14.15% | -230.75% |
| EBIT | -6.19% | -10.65% | -6.89% | -6.06% | -138.48% |
| EBITDA | -5.26% | -9.67% | -6.00% | -5.45% | -143.85% |
| EPS Basic | -7.88% | -15.30% | -5.30% | 1.62% | -187.36% |
| Normalized Basic EPS | -6.13% | -7.99% | 3.51% | 9.49% | -119.64% |
| EPS Diluted | -7.88% | -15.30% | -5.30% | 1.62% | -176.04% |
| Normalized Diluted EPS | -6.13% | -7.99% | 3.51% | 9.49% | -113.32% |
| Average Basic Shares Outstanding | 3.88% | 4.98% | 9.46% | 14.83% | 20.85% |
| Average Diluted Shares Outstanding | 3.88% | 4.98% | 9.46% | 14.83% | 20.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |